GILD - Gilead Sciences

-

$undefined

N/A

(N/A)

Gilead Sciences NasdaqGS:GILD Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Location: 333 Lakeside Drive, Foster City, CA, 94404, United States | Website: https://www.gilead.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

154.4B

Cash

8.711B

Avg Qtr Burn

N/A

Short % of Float

1.99%

Insider Ownership

0.12%

Institutional Own.

89.64%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Livdelzi (Seladelpar) Details
Primary biliary cholangitis, Primary sclerosing cholangitis, Non-alcoholic steatohepatitis , Liver disease

Approved

Quarterly sales

Trodelvy® (sacituzumab govitecan-hziy) Details
Breast cancer, ER+/HER2- breast cancer, Cancer

Approved

Quarterly sales

Yescarta® Details
B-cell lymphoma, Lymphopenia

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Biktarvy Details
Human immunodeficiency virus

Approved

Quarterly sales

Approved

Quarterly sales

Tecartus® (brexucabtagene autoleucel) (CAR-T) Details
B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia, Leukemia

Approved

Quarterly sales

Lenacapavir Details
Human immunodeficiency virus

PDUFA

Approval decision

Anito-cel Details
Multiple myeloma

Phase 3

Data readout

Trodelvy® (Sacituzumab govitecan-hziy) Details
1L metastatic triple-negative breast cancer (PD-L1-)

Phase 3

Data readout

Trodelvy + Keytruda Details
Metastatic triple-negative breast cancer (mTNBC) with PD-L1+ tumors

Phase 3

Data readout

Phase 3

Update

Phase 3

Update

Sunlenca (Lenacapavir) Details
Human immunodeficiency virus

Phase 2/3

Data readout

Phase 2b

Update

Yescarta Details
Lymphopenia, B-cell lymphoma

Phase 2

Update

Phase 2

Update

Etrumadenant Details
Colorectal cancer

Phase 2

Update

Phase 2

Update

Magrolimab+Azacitidine Details
High risk myelodysplastic syndromes

Failed

Discontinued